CN111315412A - Il-1b结合抗体用于治疗酒精性肝炎的用途 - Google Patents

Il-1b结合抗体用于治疗酒精性肝炎的用途 Download PDF

Info

Publication number
CN111315412A
CN111315412A CN201880066309.7A CN201880066309A CN111315412A CN 111315412 A CN111315412 A CN 111315412A CN 201880066309 A CN201880066309 A CN 201880066309A CN 111315412 A CN111315412 A CN 111315412A
Authority
CN
China
Prior art keywords
subject
administration
days
weeks
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880066309.7A
Other languages
English (en)
Chinese (zh)
Inventor
S·姆波夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN111315412A publication Critical patent/CN111315412A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201880066309.7A 2017-09-13 2018-09-11 Il-1b结合抗体用于治疗酒精性肝炎的用途 Pending CN111315412A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762557929P 2017-09-13 2017-09-13
US62/557,929 2017-09-13
US201862647088P 2018-03-23 2018-03-23
US62/647,088 2018-03-23
PCT/IB2018/056928 WO2019053591A1 (en) 2017-09-13 2018-09-11 USE OF IL-1B BINDING ANTIBODIES FOR THE TREATMENT OF ALCOHOLIC HEPATITIS

Publications (1)

Publication Number Publication Date
CN111315412A true CN111315412A (zh) 2020-06-19

Family

ID=63708416

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880066309.7A Pending CN111315412A (zh) 2017-09-13 2018-09-11 Il-1b结合抗体用于治疗酒精性肝炎的用途

Country Status (14)

Country Link
US (3) US20200207848A1 (enExample)
EP (1) EP3717006A1 (enExample)
JP (1) JP2020533353A (enExample)
KR (1) KR20200052331A (enExample)
CN (1) CN111315412A (enExample)
AU (1) AU2018333106A1 (enExample)
BR (1) BR112020004903A2 (enExample)
CA (1) CA3075711A1 (enExample)
CL (1) CL2020000631A1 (enExample)
IL (1) IL273204A (enExample)
MX (1) MX2020002813A (enExample)
RU (1) RU2020113234A (enExample)
TW (1) TW201920269A (enExample)
WO (1) WO2019053591A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026145640A1 (zh) * 2025-01-03 2026-07-09 长春金赛药业有限责任公司 一种抗IL-1β抗体的药物组合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1484652A (zh) * 2000-08-22 2004-03-24 ��˹��ŵ�� 人IL-1β的抗体
US20160213736A1 (en) * 2014-05-12 2016-07-28 Conatus Pharmaceuticals, Inc. Treatment of the complications of chronic liver disease
KR20160107420A (ko) * 2015-03-03 2016-09-19 한국과학기술원 진세노사이드 f2를 포함하는 비알코올성 간 질환 또는 인슐린 저항성의 예방 또는 치료용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2335232T3 (es) 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
AU2010306681A1 (en) * 2009-10-15 2012-04-19 Abbvie Inc. IL-1 binding proteins
US10000565B2 (en) * 2012-11-16 2018-06-19 Novartis Ag Use of IL-1 β binding antibodies for treating peripheral arterial disease
WO2015083120A1 (en) * 2013-12-04 2015-06-11 Novartis Ag USE OF IL-1β BINDING ANTIBODIES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1484652A (zh) * 2000-08-22 2004-03-24 ��˹��ŵ�� 人IL-1β的抗体
US20160213736A1 (en) * 2014-05-12 2016-07-28 Conatus Pharmaceuticals, Inc. Treatment of the complications of chronic liver disease
KR20160107420A (ko) * 2015-03-03 2016-09-19 한국과학기술원 진세노사이드 f2를 포함하는 비알코올성 간 질환 또는 인슐린 저항성의 예방 또는 치료용 조성물

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J KATO ET AL: "Suppressive effect of ethanol on the expression of hepatic asialoglycoprotein receptors augmented by interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha" *
刘丽琼;骆嘉;柯尊记;: "细胞因子与酒精性肝病" *
沈国定;姜润秋;孙倍成;: "炎症相关因子IL-1β,TGF-β及MCP-1在肝细胞肝癌的表达" *
黄依兰;: "清肝泄浊活血方治疗酒精性肝病疗效观察" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026145640A1 (zh) * 2025-01-03 2026-07-09 长春金赛药业有限责任公司 一种抗IL-1β抗体的药物组合物及其用途

Also Published As

Publication number Publication date
TW201920269A (zh) 2019-06-01
WO2019053591A1 (en) 2019-03-21
JP2020533353A (ja) 2020-11-19
MX2020002813A (es) 2020-07-21
AU2018333106A1 (en) 2020-04-02
US20200207848A1 (en) 2020-07-02
CA3075711A1 (en) 2019-03-21
EP3717006A1 (en) 2020-10-07
IL273204A (en) 2020-04-30
US20230235043A1 (en) 2023-07-27
US20210309736A1 (en) 2021-10-07
RU2020113234A3 (enExample) 2022-04-28
CL2020000631A1 (es) 2020-09-11
RU2020113234A (ru) 2021-10-13
KR20200052331A (ko) 2020-05-14
BR112020004903A2 (pt) 2020-09-15

Similar Documents

Publication Publication Date Title
US20190111012A1 (en) Methods of treatment of cholestatic diseases
JP7860961B2 (ja) 原発性胆汁性胆管炎の治療のための組成物及び方法
US11331292B2 (en) Methods of treatment of cholestatic diseases
US12290498B2 (en) Methods of treatment of cholestatic diseases
JP2022549621A (ja) アルコール性肝炎の処置
US20230235043A1 (en) Use of il-1b binding antibodies for the treatment of alcoholic hepatitis
TW202408522A (zh) 一種稠環嘧啶類化合物的用途
JP2023521909A (ja) 呼吸器疾患の治療
RU2754509C1 (ru) Способ лечения первичной мембранозной нефропатии с нефротическим синдромом и повышенным уровнем анти-plar2
WO2020135872A1 (zh) 免疫抑制药物组合物及其应用
WO2023143446A1 (en) Compositions and methods for treating cytokine storm
WO2026047132A1 (en) Treatment of advanced primary biliary cholangitis
CN110099686B (zh) 非酒精性脂肪性肝病的治疗
CN121081477A (zh) 丹参酮iia用于治疗湿性年龄相关性黄斑变性的用途
EA050849B1 (ru) Композиции и способы лечения первичного билиарного холангита
BR112020019172A2 (pt) tratamento e profilaxia de amiloidose
JPWO2001032213A1 (ja) 肝再生促進剤および肝不全治療薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200619

WD01 Invention patent application deemed withdrawn after publication